NanoViricides is trading 5.07% lower at $1.31, likely reflecting a sharp risk-off session weighing on growth stocks and biotechnology. - No fresh company-specific announcement explaining the November 5 move was identified; the latest company update found concerned Ebola trial progress. - A November 5 report also noted a broader biotech selloff, with the XBI ETF down 3% at the time of writing.